Suppr超能文献

皮质类固醇诱导的骨质疏松症的流行病学:一项荟萃分析。

The epidemiology of corticosteroid-induced osteoporosis: a meta-analysis.

作者信息

van Staa T P, Leufkens H G M, Cooper C

机构信息

MRC Environmental Epidemiology Unit, University of Southampton, Southampton General Hospital, Southampton, UK.

出版信息

Osteoporos Int. 2002 Oct;13(10):777-87. doi: 10.1007/s001980200108.

Abstract

Studies of oral corticosteroid dose and loss of bone mineral density have reported inconsistent results. In this meta-analysis, we used information from 66 papers on bone density and 23 papers on fractures to examine the effects of oral corticosteroids on bone mineral density and risk of fracture. Strong correlations were found between cumulative dose and loss of bone mineral density and between daily dose and risk of fracture. The risk of fracture was found to increase rapidly after the start of oral corticosteroid therapy (within 3 to 6 months) and decrease after stopping therapy. The risk remained independent of underlying disease, age and gender. We conclude that oral corticosteroid treatment using more than 5 mg (of prednisolone or equivalent) daily leads to a reduction in bone mineral density and a rapid increase in the risk of fracture during the treatment period. Early use of preventive measures against corticosteroid-induced osteoporosis is recommended.

摘要

关于口服皮质类固醇剂量与骨矿物质密度流失的研究报告结果并不一致。在这项荟萃分析中,我们利用了66篇关于骨密度的论文和23篇关于骨折的论文中的信息,来研究口服皮质类固醇对骨矿物质密度和骨折风险的影响。发现累积剂量与骨矿物质密度流失之间以及每日剂量与骨折风险之间存在强相关性。发现口服皮质类固醇治疗开始后(3至6个月内)骨折风险迅速增加,停药后则降低。该风险与基础疾病、年龄和性别无关。我们得出结论,每日使用超过5毫克(泼尼松龙或等效物)的口服皮质类固醇治疗会导致骨矿物质密度降低,并在治疗期间使骨折风险迅速增加。建议尽早采取预防措施以对抗皮质类固醇诱导的骨质疏松症。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验